Credit Suisse covered Lantheus Holdings (NASDAQ:LNTH), raising its target price to $8.00 today
- Updated: September 23, 2016
Credit Suisse raised the target price of Lantheus Holdings (NASDAQ:LNTH) to $8.00 stating a possible downside of -0.12%.
Previously on 08/29/2016, Jefferies & Co released a statement on Lantheus Holdings (NASDAQ:LNTH) raised the target price from $8.00 to $12.00. At the time, this indicated a possible upside of 0.30%.
Only yesterday Lantheus Holdings (NASDAQ:LNTH) traded -1.65% lower at $9.07. The company’s 50-day moving average is $7.83 and its 200-day moving average is $3.98. With the last close up 123.90% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 43,195 shares of Lantheus Holdings exchanged hands, down from an avg. volume of 478,291
See Chart Below
Lantheus Holdings has a P/E ratio of 10.07 with a 52 week low of $1.76 and a 52 week high of $10.10 LNTH’s total market value is presently $0.
About Lantheus Holdings (NASDAQ:LNTH)
Lantheus Holdings, Inc. develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company's portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company's Contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company's imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.